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ABSTRACT: 48 
 49 
The synthesis of three new cyclometallated platinum(II) compounds containing a para-tolyl ligand and a 50 
tridentate [C,N,N’] (cm1) or a bidentate [C,N] ligand and an additional ligand such as SEt2 (cm2) or  51 
Ph3 (cm3) is reported. The X-ray molecular structure of platinum(II) compound cm3 is also presented. 52 
Intermolecular oxidative addition of methyl iodide or iodine upon cm1, cm2 and cm3 produced six 53 
novel cyclometallated platinum(IV) compounds. The cytotoxic activity against a panel of human 54 
adenocarcinoma cell lines (A-549 lung, MDA-MB-231 and MCF-7 breast, and HCT-116 colon), DNA 55 
interaction, topoisomerase I, IIα, and cathepsin B inhibition, and cell cycle arrest, apoptosis and ROS 56 
generation of the investigated complexes are presented. The best results for antiproliferative activity 57 
were obtained for platinum (IV) compounds cm1MeI and cm1I2 arising from oxidative addition of 58 
methyl iodide and iodine, respectively, to cm1. Cyclometallated platinum(IV) compounds cm1MeI and 59 
cm3MeI induce significant changes in the mobility of DNA and, in addition, cm1MeI, cm3MeI and 60 
cm1I2, showed considerable topoisomerase IIα inhibitory activity. Moreover, the compounds exhibiting 61 
the higher antiproliferative activity (cm1MeI and cm1I2) were found to generate ROS and to supress 62 
HCT-116 colon cancer cell growth by a mixture of cell cycle arrest and apoptosis induction. 1H NMR 63 
experiments carried out in a buffered aqueous medium (pH 7.40) indicate that compound cm1MeI is not 64 
reduced by common biologically relevant reducing agents such as ascorbic acid, glutathione or cysteine. 65 
 66 
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76 
INTRODUCTION 77 
 78 
Metal containing anticancer drugs started to be relevant more than 40 years ago with the discovery of 79 
the therapeutic potential of cisplatin. More recently, platinum(IV) compounds have attracted great 80 
interest due to their advantages over platinum(II) analogues.1–6 Platinum(IV) compounds exhibit an 81 
octahedral coordination that permits the modification of some important physicochemical properties 82 
such as lipophilicity, stability and the reduction potential through the two extra coordination positions. 83 
Moreover, they are kinetically inert compared to platinum(II) analogues, which allows the possibility of 84 
oral administration. 85 
On the other hand, platinum(II) cyclometallated compounds, especially those with nitrogen donor atoms, 86 
attract great interest due to their antitumour properties.7 They benefit from a strong σ(M–C) bond that 87 
improves their stability in front of biological reduction and labilises the trans ligands allowing the 88 
exchange in cellular uptake. 89 
Surprisingly, very little attention has been devoted to cyclometallated platinum(IV) compounds although 90 
these species combine the properties imparted by the presence of a platinum(IV) centre and a 91 
cyclometallated ligand. We have recently reported the synthesis and biological studies of several 92 
cyclometallated platinum(IV) compounds that were prepared either by intramolecular C–X bond 93 
activation from an adequate platinum(II) substrate and a potentially tridentate [C,N,N′] ligand (method 94 
A in Scheme 1)8,9 or, more recently, by intermolecular oxidative addition of Y–Z reagents such as 95 
methyl iodide or iodine10 on a [C,N,N′]-cyclometallated platinum(II) precursor containing an additional 96 
ligand such as Cl, I or CH3 (method B in Scheme 1). This second method allows comparison of the 97 
biological properties of the platinum(IV) compounds with the parent platinum(II) precursors. 98 
During these studies, it has been found that cyclometallated platinum(IV) compounds containing three 99 
Caryl-donor ligands (1a, 1a′, 1b′) and those containing two or three C-donor ligands including one axial 100 
methyl (2a–2c) displayed a remarkable cytotoxicity against several cancer cell lines in spite of their 101 
reluctance to be reduced.9,10 In view of these findings, we decided to further explore this type of 102 
cyclometallated platinum(IV) compound. In particular, the aim of this work is to study new 103 
cyclometallated platinum(IV) compounds obtained through oxidative addition of both methyl iodide and 104 
iodine (method B) on cyclometallated platinum(II) containing an additional aryl ligand. This aryl ligand 105 
places an additional C-donor ligand in the coordination sphere of platinum and increases the 106 
polarizability of the obtained compounds. In addition, the presence of an aryl ligand might favour 107 
intercalative binding to DNA through π–π stacking. 108 
On the other hand, the presence of a triphenylphosphine ligand has been reported to increase the 109 
lipophilicity of cyclometallated palladium(II) and platinum(II) compounds leading to high cytotoxicity 110 
of these compounds.11–13 Stable platinum(IV) compounds containing triphenylphosphine ligand have 111 
been reported to be active against cancer cell lines.14 We therefore decided to include in the present 112 
study, in addition to [C,N,N′]-cyclometallated platinum(II) compound cm1, compounds containing a 113 
[C,N]-platinacycle and an additional ligand such as SEt2 or PPh3 (cm2 and cm3 shown in Scheme 2, 114 
respectively) which should allow us to compare the effect of these additional ligands on the biological 115 
properties of these compounds. The platinum(II) precursors selected in this study are shown in Scheme 116 
2. 117 
118 
SYNTHESIS OF THE COMPOUNDS 119 
 120 
Synthesis of cyclometallated platinum(II) compounds 121 
Cyclometallated platinum(II) compounds were prepared following known procedures from dinuclear 122 
platinum complex [Pt(4-CH3C6H4)2{μ-S(CH2CH3)2}]2 (A) and two different imines, L1 containing 123 
two nitrogen atoms and L2 containing one nitrogen atom.15 The reaction with L1 takes place through 124 
initial [N,N′] coordination of the imine to the platinum followed by an intramolecular C–H bond 125 
activation of the aryl ring of the imine, and elimination of a toluene molecule to produce a [C,N,N′]-126 
cyclometallated platinum(II) compound cm1 shown in Scheme 3. Evidence of the tridentate 127 
coordination of the imine ligand is obtained from the 1H NMR spectrum in which the methylamino 128 
moiety, the imine and the aromatic proton adjacent to the metallated site (Hc) are coupled to 195Pt. The 129 
ortho protons of the para-tolyl group are also coupled to 195Pt. In addition, elemental analysis and mass 130 
spectrometry are consistent with the proposed structure. 131 
In a similar process, the reaction with L2 produces a [C,N]-cyclometallated platinum(II) compound cm2 132 
shown in Scheme 3. It is interesting to point out that for imine L2, C–H bond activation could take place 133 
at the 4-chlorophenyl or at the benzylic group. The former would give an endo-metallacycle (containing 134 
the imine group) while the latter would produce an exo-metallacycle. As previously observed for similar 135 
systems,15 the reaction takes place selectively at the 4-chlorophenyl ring leading to a more stable endo 136 
five-membered cycloplatinated compound. Compound cm2 is characterized by 1H NMR spectroscopy, 137 
elemental analyses and mass spectrometry. The imine and the aromatic proton adjacent to the metalation 138 
site are coupled to 195Pt, thus confirming the bidentate [C,N] coordination of the imine. 139 
Compound cm3 (shown in Scheme 3) was prepared from reaction of cm2 with PPh3 in acetone for 2 h 140 
at room temperature that produced the substitution of the diethyl sulphide ligand by the PPh3 ligand. In 141 
the 1H NMR spectrum, the imine proton appears coupled to 195Pt, but the aromatic proton adjacent to 142 
the metallation site (Hc) could not be identified due to the higher complexity of the aromatic region 143 
arising from the presence of PPh3 protons. The 31P{1H} NMR spectrum displays one signal at 26.90 144 
ppm for which the 1J (P–Pt) value (2201.3 Hz) is consistent with the presence of an aryl ligand trans to 145 
the P atom in a platinum(II) compound.15–18 Compound cm3 was also identified by mass 146 
spectrometry, elemental analysis and X ray diffraction analysis of suitable crystals grown from 147 
CH2Cl2/MeOH (1 : 1) solution. 148 
The crystal structure is composed of discrete molecules held together by van der Waals interactions. The 149 
asymmetric unit contains two independent molecules with bond parameters equal within experimental 150 
error [3σ], one methanol and two water molecules. The molecular structure (molecule a) is shown in 151 
Fig. 1. The square-planar geometry around the platinum(II) is completed with a [C,N] ligand, a PPh3 152 
and a para-tolyl which is tilted 84.52° from the mean coordination plane. The two C-donor ligands are 153 
mutually cis as expected from the high trans influence of these ligands and the PPh3 ligand is trans to 154 
the cyclometallated aryl. As expected, the [C,N] metallacycle exhibits an endo structure (including the 155 
imine double bond). Bond lengths and angles are well within the range of values obtained for analogous 156 
compounds.15–18 In particular the imine CvN bond length lies in the usual range, resulting in a shorter 157 
distance than those reported for C–N bonds. The angles in the coordination sphere of platinum are close 158 
to 90° with the smallest angle corresponding to the metallacycle (C(8)–Pt–N(1) = 79.9(3)°). 159 
 160 
Synthesis of cyclometallated platinum(IV) compounds 161 
One of the most used methods for the preparation of octahedral platinum(IV) compounds from 162 
appropriate platinum(II)precursors proceeds via two-electron oxidation of the metal by the addition of a 163 
X–Y molecule to give products with an increased coordination number, due to the formation of two new 164 
bonds upon complete dissociation of the X–Y bond, and the corresponding evolution to an octahedral 165 
geometry.19–21 166 
In this study, oxidative addition reactions were performed by the addition of I2 and CH3I molecules to 167 
platinum(II) compounds previously prepared. Different mechanisms have been proposed for these 168 
reagents,19,22 although leading in both cases to trans oxidative addition. Oxidative addition reactions of 169 
I2 and CH3I were carried out on the three previously prepared platinum(II) compounds resulting in the 170 
formation of six different platinum(IV) products (cm1I2, cm1MeI, cm2I2, cm2MeI, cm3I2, cm3MeI). 171 
These new compounds were characterized by 1H and 31P{1H} NMR spectroscopies (for cm3MeI), 172 
elemental analysis and mass spectrometry except for compounds cm2I2 and cm3I2 that have a low 173 
solubility in common solvents and were not studied further. 174 
As shown in Table 1, the coupling constant 3J(H–Pt) value observed for the imine proton decreases 175 
when platinum(II) is oxidised to platinum(IV) compounds in agreement with previous studies for 176 
analogous compounds.23,24 Compounds arising from oxidative addition of methyl iodide display a 177 
methylplatinum resonance in the range 1.31–1.85 ppm for which the 2J(H–Pt) values (68–72 Hz) are in 178 
the range expected for platinum(IV) compounds.10,23 Moreover, addition of methyliodide in the axial 179 
positions of the platinum(II) precursors result in the loss of the symmetry plane and as a consequence 180 
non-equivalence of the methylamino protons (Hj) and the ortho protons of the para-tolyl (Ha) is 181 
observed for cm1MeI. Although we might expect that the non-equivalence of Ha protons depends upon 182 
the rate of rotation of the tolyl ligand around the Pt–C bond, the spectra taken in CDCl3 at 298 K or at 183 
323 K did not show significant differences in the chemical shifts of these protons. For cm2MeI and 184 
cm3MeI, the higher complexity of the aromatic region did not allow unequivocal assignment of the 185 
ortho protons (Ha) of the para-tolyl ligand. However, non-equivalence of the methylene Hg protons 186 
could be observed for these compounds. 187 
The changes observed in the signal corresponding to the ortho protons of the para-tolyl ligand (Ha) 188 
deserves some comment. This signal appears as a doublet at 7.39 ppm [3J (Pt–H) = 64.0 Hz] for 189 
compound cm1 and is considerably downfield shifted (δ = 8.43 ppm) for platinum(IV) compound cm1I2 190 
as a result of the interaction of Ha with axial iodide ligands. For platinum(IV) compound cm1MeI, the 191 
Ha protons are non-equivalent and only one is downfield shifted to δ =8.64 ppm while the other appears 192 
at 7.12 ppm. The para-tolyl ligand is expected to be nearly orthogonal to the plane containing the 193 
metallacycle in the solid state as observed for cm3, but it could undergo rotation in solution. At 194 
temperatures up to 323 K, the rate of rotation is slow so that a large separation in chemical shift of the 195 
diastereotopic Ha protons is observed. 196 
The reaction of cm3 containing a PPh3 ligand with methyl iodide was followed by 31P{1H} NMR 197 
spectra. Initially, a signal at −12.40 ppm coupled to 195Pt (1J (P–Pt) = 983.2 Hz) is observed; both the 198 
chemical shift and the coupling constant which is consistently reduced from that of the platinum(II) 199 
precursor indicate formation of a platinum(IV) compound. After several hours a new signal appears at 200 
−9.47 ppm (1J (P–Pt) = 989.7 Hz) and after 48 hours at room temperature this new signal fully replaces 201 
the initial compound. These observations are fully consistent with previous observations for analogous 202 
compounds for which initial trans arrangement of the added methyl and iodido ligands is followed by 203 
isomerisation to place the bulky triphenylphosphine ligand in an axial position trans to the methyl 204 
ligand.25 This process (depicted in Scheme 4) reduces the steric effects arising from the PPh3 ligand 205 
while maintaining the stable fac-PtC3 configuration of the platinum(IV) compound.23,25 206 
In order to complete the characterisation of the studied compounds, 195Pt NMR spectra were taken for 207 
the mostsoluble compounds cm1, cm1I2 and cm1MeI and the obtained values are shown in Table 1. As 208 
platinum increase its oxidation state and coordination number, the electronic density decreases, leading 209 
to a deshielding and higher frequency shifts. In particular, a higher deshielding is observed for cm1MeI 210 
versus cm1I2 in agreement with the presence of a more covalent Pt–Me bond.26,27 211 
 212 
Solution studies: stability and behaviour in the presence of ascorbic acid, glutathione and L-213 
cysteine 214 
The stability of platinum(IV) compound cm1MeI in the aqueous biological media was evaluated 215 
recording the 1H NMR spectra of the compound (1 mM) in 50 mM phosphate buffer (in D2O, pD 7.40); 216 
2 drops of deuterated DMSO were added to solubilise the compound in the media. The obtained spectra, 217 
shown in the ESI (Fig. S1†), were compared with those obtained at different storage periods. Compound 218 
cm1I2 was too insoluble as to carry out similar studies. 219 
As previously reported for cyclometallated platinum(IV) compounds containing a fac-PtC3 geometry 220 
and a mer-[C,N,N′] arrangement of the tridentate ligand,9 compound cm1MeI display several singlet 221 
signals (δ = 8.58, 8.63 and 8.69 ppm) in the imine region. This result is consistent with the ‘quasilabile’ 222 
nature of platinum(IV) complexes containing three Pt–C bonds28 so that D2O or d6-DMSO can replace 223 
the more labile ligands (N-donor or iodido ligands) leading to a mixture of solvato complexes as shown 224 
in Scheme 5. Moreover, easy mer/fac isomerisation of the [C,N,N′] ligand has also been reported for this 225 
type of compounds.28,29 Interestingly, no doublet corresponding to Ha is observed at ca. 8.5 ppm, 226 
which might suggest that the iodido ligand dissociates from the platinum(IV). No further changes are 227 
observed in the 1H NMR after one week indicating that the solvato species remain stable. 228 
Since it is generally accepted that platinum(IV) compounds are rapidly reduced under physiological 229 
conditions by biologically relevant reducing agents, the reactions of cm1MeI with ascorbic acid, 230 
glutathione and cysteine were also monitored by 1H NMR spectroscopy under analogous conditions and 231 
the obtained spectra are given in the ESI (Fig. S2–S4†). For the reaction with ascorbic acid, the imine 232 
region was most informative since in this region neither the solvents nor the ascorbic acid interfere with 233 
the products signals. In this case, only one signal is observed in the imine region at 8.61 ppm. The J(H–234 
Pt) value obtained for this new species is 42.3 Hz which suggests that the platinacycle is not cleaved, 235 
and that the platinum(IV) is not reduced. The downfield shifted aromatic doublet is not observed, 236 
therefore we might deduce that the ascorbic acid can coordinate to the platinum replacing the iodido 237 
ligand as shown in Scheme 5. The newly formed compound is stable for 24 hours, however the spectrum 238 
taken after one week indicates that the intensity of the signal at 8.61 ppm decreases while a new 239 
resonance at 8.69 ppm [J = 45.2 Hz] appears. These values also correspond to a platinum(IV) 240 
metallacycle, therefore no reduction occurs and just minor changes in the coordination sphere of the 241 
platinum or the coordination mode of the ascorbic acid take place after one week (Fig. S2†). 242 
Finally, for the reaction with glutathione (Fig. S3†) and L-cysteine (Fig. S4†) formation of novel species 243 
is clearly detected at the early stages of the process. For the reaction with glutathione, two resonances at 244 
8.57 ppm [3J(H–Pt) = 43.0 Hz] and 8.55 ppm [3J(H–Pt) = 41.0 Hz] in the imine region and two 245 
resonances at 0.61 ppm [2J(H–Pt) = 64.0 Hz] and 0.58 ppm [2J(H–Pt) = 63.7 Hz] in the methyl region 246 
are observed. For the reaction with cysteine, two resonances at 8.60 ppm [3J(H–Pt) = 42.4 Hz] and 8.62 247 
ppm [3J(H–Pt) = 40.9 Hz] in the imine region, and one resonance at 0.57 ppm [2J(H–Pt) = 70.0 Hz] in 248 
the methyl region are observed. In both cases, the observed values of the coupling constants are in the 249 
range expected for platinum(IV) compounds, thus suggesting coordination of the glutathione or the 250 
cysteine (see Scheme 5) rather than reduction of the platinum(IV). In particular, the values of 2J(H–Pt) 251 
for the axial methyl ligand are well within the range observed for methylplatinum(IV) with S-donor or 252 
N-donor ligands in trans.23 In agreement with the lower trans influence of O-donor ligands, slightly 253 
higher values of 2J(H–Pt) (75–77 Hz) have been reported for methylplatinum(IV) with O-donor ligands 254 
in trans.30,31 Although there is only a small difference in the 2J(H–Pt) values, we might tentatively 255 
suggest that coordination of cysteine and glutathione to platinum(IV) possibly takes place through either 256 
S or N donor atoms. While for cysteine, the new formed species are stable after one week, for 257 
glutathione the intensity of these signals decrease after 24 hours to produce rather complex spectra 258 
which suggest a fast decomposition of these species. 259 
As a whole, in agreement with our previous studies concerning cyclometallated platinum(IV) 260 
compounds containing a fac-PtC3 geometry,9 these compounds are reluctant to be reduced while they 261 
display a high lability due to the presence of three Pt–C bonds. 262 
The reduction of platinum(IV) complexes has been the subject of many studies, most of them involving 263 
compounds containing chlorido, hydroxido or carboxylato ligands in the axial positions, and several 264 
mechanisms have been proposed for the reductive elimination such as outer sphere, inner sphere and 265 
platinum(II) catalysed reactions.32–35 The different axial ligands present in compound cm1MeI might 266 
define distinct reactivity patterns for this compound so that the presence of a methyl ligand favours 267 
substitution of the trans-iodido ligand as well as a higher stability of the oxidation state(IV) of the 268 
platinum. 269 
270 
BIOLOGICAL STUDIES 271 
 272 
Antiproliferative assay 273 
The antiproliferative activity of cyclometallated platinum(II) (cm1, cm2 and cm3) and cyclometallated 274 
platinum(IV) (cm1I2, cm1MeI, cm2MeI and cm3MeI) complexes along with cisplatin, as a positive 275 
control, was determined by the MTT assay. Compounds cm2I2 and cm3I2 were not considered due to 276 
their low solubility. The non-small A-549 lung, HCT-116 colon and MCF-7 and MDA-MB-231 breast 277 
adenocarcinoma cell lines were used in the study. The half-maximal inhibitory concentration (IC50) 278 
values of cisplatin and the investigated compounds evaluated after 72 h of drug exposure are depicted in 279 
Table 2 and Fig. 2. 280 
Platinum(II) compounds cm1 and cm2 exhibited cytotoxicity in all the carcinoma cell lines selected in a 281 
similar range to that observed for previously reported compounds 1a–1c. Contrary to our expectations, 282 
compound cm3 containing a triphenylphosphine ligand did not exhibit cytotoxicity in these cell lines. 283 
This result suggests that the presence of a particular ligand per se may not imply cytotoxicity of the 284 
platinum compound. Interestingly, for palladium or platinum(II) derivatives giving good results the 285 
triphenylphosphine ligand is trans to a relatively labile N-donor and might increase its lability11,13 286 
while in the present case the phosphine is trans to a non-labile C-donor. 287 
The platinum(IV) compounds arising from oxidative addition of methyl iodide (cm1MeI) or iodine 288 
(cm1I2) to cm1 are the most potent. In particular, cm1MeI shows a special sensitivity for MDA-MB231 289 
breast (IC50 = 1.56 μM) and HCT-116 colon (IC50 = 1.77 μM) cancer cells. The obtained IC50 values 290 
in all studied cell lines are in the same range than those previously reported by us for compounds 2b and 291 
2c shown in Scheme 1. 292 
Interestingly, compounds cm1MeI and cm1I2, as depicted in Fig. 3 and 4, showed a lower 293 
antiproliferative activity in normal human foreskin fibroblast cells (BJ) than that in the adenocarcinoma 294 
cell lines tested, indicating a desirable selectivity for tumour cells. For the most potent investigated 295 
compound cm1MeI this effect is seen at 5 and 10 μM concentration of compound, whereas for 296 
compound cm1I2 it is seen at 10, 25 and 50 μM concentration of compound. 297 
These results confirm that [C,N,N′]-cyclometallated platinum(IV) compounds containing either a fac-298 
PtC3 arrangement and one iodido ligand or a cis-PtC2 moiety and two iodide ligands are promising 299 
candidates as antitumor agents, while the nature of the C-donor ligand (methyl or aryl) is not relevant. In 300 
contrast, cyclometallated [C,N] platinum(IV) compounds cm2MeI and cm3MeI which also display a 301 
fac-PtC3 arrangement were considerably less potent than cyclometallated [C,N,N′] compound cm1MeI. 302 
As a whole, these results suggest that the presence of a particular ligand or the specific arrangement of 303 
the ligands may not produce the desired biological behaviour of a platinum compound, which is 304 
generally governed by an interplay of several factors. 305 
 306 
 307 
DNA interaction 308 
The interaction of cyclometallated platinum(II) cm1, cm2 and cm3, and cyclometallated platinum(IV) 309 
complexes cm1MeI, cm1I2, cm2MeI and cm3MeI with DNA was studied by their ability to modify the 310 
electrophoretic mobility of the supercoiled closed circular (sc) and the open circular (oc) forms of 311 
pBluescript SK+ plasmid DNA. The sc form usually moves faster due to its compact structure. To 312 
provide a basis for comparison, incubation of DNA with cisplatin and ethidium bromide (EB) was also 313 
performed using the same conditions. 314 
On the basis of the gel mobility shift assay (see Fig. 5) platinacycles cm1MeI and cm3MeI induce 315 
significant changes in the mobility of plasmid DNA, altering the DNA tertiary structure as the standard 316 
reference, cisplatin. Complex cm1MeI shows an interaction with plasmid DNA at concentrations greater 317 
than or equal to 100 μM, which are much higher than the concentrations for cisplatin. On the other hand, 318 
complex cm3MeI induces important changes at relatively low concentrations, as 25 μM. Platinacycles 319 
cm1, cm2, cm3, cm1I2 and cm2MeI were not efficient in removing the supercoils from DNA. 320 
To evaluate the ability of the investigated platinum(II) and platinum(IV) complexes to intercalate into 321 
DNA, a topoisomerase-based gel assay was performed with the same complexes used in the previous 322 
assay. Supercoiled pBluescript plasmid DNA was incubated in the presence of topoisomerase I at 100 323 
μM concentration of compounds under study. 324 
The results are given in Fig. 6 and they show that none of the tested compounds prevent unwinding of 325 
DNA by the action of topoisomerase I, indicating that these compounds are neither intercalators nor 326 
topoisomerase I inhibitors, thus pointing out to another biological target.36 327 
To study an alternative biomolecular target, a topoisomerase IIα-based gel assay was performed. This 328 
enzyme controls and alters the topologic states of DNA during transcription and catalyses the transient 329 
breaking and rejoining of two strands of duplex DNA, thus altering its topology. This enzyme is the 330 
target for several anticancer agents.37 Supercoiled pBluescript plasmid DNA was incubated at 37 °C in 331 
the presence of topoisomerase IIα at increasing concentrations of compounds under study. The gel 332 
mobility shift assay shows (see Fig. 7) that compounds cm1MeI, cm3MeI and cm1I2 were able to 333 
inhibit the action of topoisomerase IIα at low concentrations. Platinacycle cm2MeI was much less 334 
efficient in inhibiting the enzyme activity because its effective concentration is 100 μM. Platinum(II) 335 
complexes tested do not show any inhibition activity. 336 
 337 
Cathepsin B inhibition 338 
Cathepsin B is a cysteine metalloprotease highly upregulated in a wide variety of cancers by 339 
mechanisms ranging from gene amplification to post-transcriptional modification. The exact role of 340 
cathepsin B in solid tumours has yet to be defined, but it has been proposed to participate in metastasis, 341 
angiogenesis, and tumour progression. Recently, compounds based on palladium, platinum, ruthenium, 342 
gold and tellurium were shown to be effective inhibitors of cathepsin B.9,11,38 343 
In this study, compounds cm1, cm2, cm3, cm1I2, cm1MeI, cm2MeI and cm3MeI in a 50 μM and 100 344 
μM concentrations were submitted to a cathepsin B inhibition assay. Results show that none of the 345 
studied compounds presents significant inhibitory activity against cathepsin B at both concentrations 346 
tested. The residual activity was in all cases greater than 50% (Table 3). 347 
 348 
Effect of compounds cm1MeI and cm1I2 on cell cycle distribution 349 
The cell cycle is a series of sequential and tightly regulated events that a cell must undergo before each 350 
division by mitosis. These events are classified into three distinct phases: first, G0/G1, in which a cell 351 
may be quiescent (G0) or preparing for its DNA replication (gap1 or G1); synthesis (S), in which the 352 
cell is duplicating its own genome; and G2/M (gap2 and mitosis), in which a cell actually generates an 353 
exact copy of itself. Given the importance of this whole process, it is strictly regulated by several 354 
checkpoints and signalling cascades that avoid uncontrolled cell proliferation or proliferation of 355 
damaged cells. Precisely, the dysfunction of these checkpoints is one of the key driving forces of 356 
oncogenic transformation39–41 and thus inhibiting cell proliferation through cell cycle arrest constitutes 357 
an attractive approach in cancer therapy research. 358 
Compounds cm1MeI and cm1I2 were selected as representative of the set of platinum(IV) novel species, 359 
since they present higher efficacy in limiting cell proliferation of different cancer cell lines, especially in 360 
the highly-proliferative HCT-116 colon cancer model. Changes in cell cycle distribution of HCT-116 361 
were evaluated after a 72 h incubation with half maximal inhibitory concentrations (IC50) of either 362 
cm1MeI or cm1I2, analysed by Fluorescence Activated Cell Sorting (FACS), staining DNA content 363 
with propidium iodide (PI). Our results (Fig. 8) show that both compounds cause a decrease in the 364 
percentage of cells in G0/G1 phase, while inducing an S and G2/M cell cycle arrest, indicating that both 365 
compounds inhibit cell proliferation by hindering cell cycle completion.42 366 
 367 
Effect of compounds cm1MeI and cm1I2 on apoptosis 368 
When cell cycle checkpoints are fully functional, damaged cells cannot progress through cell cycle 369 
phases. Instead, cell signalling cascades redirect those damaged cells into programmed cell death or 370 
apoptosis. However, as with cell cycle checkpoints, cancer cells are also able to counteract apoptotic 371 
stimuli by activating oncogenes that promote cell survival and proliferation.43 Thus, counteracting this 372 
anti-apoptotic oncogenic activation and selectively inducing apoptosis in cancer cells is also an 373 
appealing therapeutic window. For this reason, pro-apoptotic effect of compounds cm1MeI and cm1I2 374 
on HCT-116 was also investigated. Cells were incubated for 72 h with either cm1MeI or cm1I2 at half 375 
maximal inhibitory concentration (IC50) and the relative populations of alive, preapoptotic and 376 
apoptotic/necrotic cells were measured by FACS, by simultaneously labelling the cells with fluorescein-377 
annexin V (AV-FITC, annexin V-fluorescein isothiocyanate) and propidium iodide. 378 
Annexin V-FITC is a fluorescent probe used to detect early apoptotic cells since it binds to 379 
phosphatidylserine (PS) residues on the outer membrane of the cell, process that only occurs as one of 380 
the initial steps of the apoptotic program.44,45 On the other hand, propidium iodide is a fluorescent 381 
probe that binds to DNA and is able to stain all cells. However, the signal of the late apoptotic/necrotic 382 
cell population is much more intense than the one of alive or early apoptotic cells, since cell membrane 383 
integrity is lost at late stages of both cell death programs and larger amounts of PI can permeate the cell 384 
membrane.45 Flow cytometry analysis of cells stained with both probes allows us to relatively quantify 385 
three cell populations: alive cells (low PI/low annexin-V), early apoptotic cells (low PI/high annexin-V) 386 
and late apoptotic/necrotic cells (high PI). 387 
Both cm1MeI and cm1I2 significantly trigger apoptosis in HCT-116 cells, as shown in Fig. 9. A 72 h 388 
incubation with cm1MeI at the IC50 dose caused a 50% decrease in the percentage of healthy cells, 389 
whereas early apoptotic and apoptotic/ necrotic cells presented 32% and 18% increases respectively. 390 
Compound cm1I2 incubation at the IC50 dose for 72 h resulted in a 15% decrease in healthy cell 391 
population and a consequent similar increase in late apoptotic or necrotic cells and a nonsignificant 392 
increase in early apoptotic cells at 72 h. These results highlight the potential suitability of both cm1MeI 393 
and cm1I2 as chemotherapeutic agents. 394 
 395 
Generation of reactive oxygen species (ROS) 396 
Reactive oxygen species (ROS) are oxidant by-products of cell metabolism, including superoxide 397 
(O2−), hydrogen peroxide (H2O2), hydroxyl radical (•OH) and singlet oxygen (1O2). In normal 398 
physiological conditions, ROS levels are low and they contribute to cell survival, proliferation, 399 
homeostasis and cell signalling.46–48 On the contrary, high ROS levels are linked to stress and 400 
pathological conditions and produce damage to DNA, proteins, and lipids, thus activating cell damage-401 
responsive barriers that can lead to cell senescence or apoptosis triggered by cytochrome c release from 402 
the mitochondria.49,50 In particular, cancer cells are able to maintain higher ROS levels while evading 403 
these apoptotic programs. This feature permits sustained DNA damage and genomic instability and 404 
allows the constant evolution of tumour cell populations.51 Cisplatin mechanism of action in cancer 405 
cells involves further ROS production to an extent which cancer cells can no longer evade 406 
apoptosis.52,53 407 
As part of the validation of the cytotoxic effect of compounds cm1MeI and cm1I2 on cancer cells, ROS 408 
generation on HCT-116 cell line was evaluated. HCT-116 cells were incubated with cm1MeI and cm1I2 409 
at their half maximal inhibitory concentrations (IC50) for 24, 48 and 72 h and then analysed in a flow 410 
cytometer after exposure to DFCH-DA (2′,7′-dichlorofluorescein diacetate), a fluorescent probe that 411 
measures hydroxyl, peroxyl, and other ROS activities. Our findings suggest that significant increased 412 
ROS generation occurs for both compounds only after 72 h of incubation, as shown in Fig. 10. These 413 
results agree with previous studies that reported enhanced ROS generation in cancer cells as a response 414 
to platinum(IV) complexes.54,55 415 
416 
CONCLUSIONS 417 
 418 
New cyclometallated platinum(IV) compounds were obtained from intermolecular oxidative addition of 419 
either methyl iodide or iodine to platinum(II) precursors containing a para-tolyl ligand and a terdentate 420 
[C,N,N′] (cm1) or a bidentate [C,N] and an additional ligand such as SEt2 (cm2) or PPh3 (cm3). The 421 
compounds were characterized by mass-spectrometry, elemental analyses and NMR spectroscopy 422 
except for cm2I2 and cm3I2 that were too insoluble in common solvents and were not studied further. 423 
The molecular structure of platinum(II) compound cm3 was solved by X ray analyses. 424 
The cytotoxic activity against a panel of human adenocarcinoma cell lines (A-549 lung, MDA-MB-231 425 
and MC-7 breast, and HCT-116 colon) was determined for the new platinum(IV) compounds and the 426 
platinum(II) precursors. Most compounds exhibited a remarkable cytotoxicity in all the selected cancer 427 
cell lines, in particular compounds cm1I2 and cm1MeI containing a terdentate [C,N,N′] ligand are the 428 
most potent. The studies on electrophoretic mobility of DNA indicated that platinum(II) compounds 429 
cm1, cm2 and cm3 and platinum(IV) compounds cm1I2 and cm2MeI were not effective in removing the 430 
plasmid DNA supercoils. In contrast, platinacycles cm1MeI and cm3MeI induce significant changes in 431 
the mobility of DNA. Topoisomerase-based gel assays indicated that none of the studied compounds are 432 
intercalators or topoisomerase I inhibitors, but platinum(IV) compounds cm1MeI, cm3MeI and cm1I2, 433 
and to a lesser extent cm2MeI showed considerable topoisomerase IIα inhibitory activity. In contrast, 434 
none of the tested compounds inhibits cathepsin B. 435 
Both cm1MeI and cm1I2 were found to supress HCT-116 colon cancer cell growth by a mixture of cell 436 
cycle arrest and apoptosis induction and to increase ROS levels. 1H NMR studies carried out in a 437 
buffered aqueous medium for platinum(IV) compound cm1MeI in the presence of biologically relevant 438 
reducing agents such as ascorbic acid, glutathione or cysteine indicated coordination of these molecules 439 
to platinum(IV) without reduction to a platinum(II) species. The capacity of cm1MeI to coordinate such 440 
molecules may explain its ability to induce ROS by capturing ROS-scavenging agents, preventing the 441 
cell of successful detoxification of oxidative damage, which may contribute to its cytotoxicity. 442 
The multitarget nature and the low solubility of some of the investigated compounds may account for 443 
the difficulties encountered to establish reliable structure–activity relationships. The [C,N,N′]-444 
cyclometallated platinum(IV) compound cm1MeI containing a fac-PtC3 arrangement and one iodide 445 
ligand can be considered a promising candidate as antitumor agent. This compound, more potent than 446 
the parent platinum(II) compound cm1, trigger antiproliferative activity by interacting with DNA (in a 447 
similar way than cisplatin but in a lesser extend) and inhibiting topoisomerase-IIα. In contrast, 448 
cyclometallated [C,N] platinum(IV) compounds cm2MeI and cm3MeI which also display a fac-PtC3 449 
arrangement were considerably less potent than cm1MeI. Moreover, in spite of their similar structure 450 
with the potent antiproliferative [C,N,N′]-cyclometallated platinum(IV) compound cm1I2, the low 451 
solubility of cyclometallated [C,N] platinum(IV) compounds cm2I2 and cm3I2 prevent their study as 452 
antitumor agents. In addition, the obtained results also indicate that the presence of a triphenylphosphine 453 
instead of a diethylsulfide ligand leads to decreased activity for both platinum(II) and platinum(IV) 454 
compounds containing a [C,N] cyclometallated ligand. 455 
As a whole, the studies here presented indicate that the new cyclometallated platinum(IV) compounds 456 
cm1I2 and cm1MeI containing a terdentate [C,N,N′] ligand display a high potential to be used in cancer 457 
chemotherapy in spite of their low proclivity to be reduced. 458 
 459 
460 
EXPERIMENTAL SECTION 461 
 462 
Chemistry 463 
Microanalyses were performed at the Centres Científics I Tecnològics (Universitat de Barcelona) using 464 
a Carlo Erba model EA1108 elemental analyser. Electrospray mass spectra were performed at the Unitat 465 
d’Espectrometria de Masses (Universitat de Barcelona) in a LC/MSD-TOF spectrometer using H2O–466 
CH3CN 1 : 1 to introduce the sample. NMR spectra were performed at the Unitat de RMN d’Alt Camp 467 
de la Universitat de Barcelona using a Mercury-400 (1H, 400 MHz) or a Bruker 400 Avance III 468 
(31P{1H} NMR, 161.98 MHz; 195Pt, 85.68 MHz) and referenced to SiMe4 (1H), to H3PO4 (31P) or to 469 
H2PtCl6 in D2O (195Pt). δ values are given in ppm and J values in Hz. Abbreviations used: s = singlet; 470 
d = doublet; t = triplet; m = multiplet. 471 
Preparation of the complexes. All reagents were obtained from commercial sources and used as 472 
received. Ligands 4-ClC6H4CHN(CH2)3N(CH3)2 (L1) and 4-ClC6H4CHNCH2Ph (L2)16 and 473 
compound [Pt(4-CH3C6H4)2{μ-S(CH2CH3)2}]2 (A)56 were prepared as reported elsewhere. 474 
 475 
Cyclometallated platinum(II) compounds: synthesis and characterization 476 
[Pt(4-CH3C6H4){(CH3)2N(CH2)3NCH(4-ClC6H3)}] (cm1). 0.200 g (0.21 mmol) of compound A and 477 
0.096 g (0.43 mmol) of 4-ClC6H4CHNCH2CH2N(CH3)2 (L1) were dissolved in 25 mL of toluene and 478 
stirred at 90 °C for 6 h. The mixture was evaporated to dryness obtaining an orange oil. Addition of 479 
diethylether induced precipitation and the orange powder was filtered and dried. Yield: 0.131 g (60%). 480 
1H NMR (400 MHz, CDCl3): δ 8.48 [s, 3J(H–Pt) = 56.0; 1H, Hf ], 7.39 [d, 3J(H–H) = 8.0; 3J(H–Pt) = 481 
64.0; 2H, Ha], 7.14 [d, 3J(H–H) = 8.0; 1H, He], 6.92 [d, 3J(H–H) = 8.0; 2H, Hb], 6.88 [dd, 3J(H–H) = 482 
8.0; 4J(H–H) = 2.0; 1H, Hd], 6.64 [d, 4J(H–H) = 1.6; 3J(H–Pt) = 66.8; 1H, Hc], 3.83 [td, 3J(H–H) = 5.2; 483 
4J(H–H) = 1.6; 2H, Hg], 2.89 [m, 2H, Hh], 2.58 [s, 3J(H–Pt) = 23.2; 6H, Hj], 2.30 [s, 3H, Hk], 2.06 [m, 484 
2H, Hi]. 195Pt NMR (85.68 MHz, CDCl3): δ −3699.1 (s). Anal.: calc. C19H23ClN2Pt (%): C, 44.75; 485 
H, 4.55; N, 5.49. Found (%): C, 44.18; H, 5.17; N, 5.24. MS-ESI(+): m/z: 509.12 [M]+, 419.06 [M-486 
tolyl]+. 487 
[Pt(4-CH3C6H4){(C6H5CH2)NCH(4-ClC6H3)}(S(CH2CH3)2)] (cm2). A 0.201 g (0.21 mmol) amount 488 
of compound A and 0.102 g (0.44 mmol) of 4-ClC6H4CHNCH2C6H4 (L2) were combined in 25 mL of 489 
toluene and stirred at room temperature for 24 h. The solvent was evaporated obtaining an orange oil. 490 
This residue was treated with hexane to yield a yellow solid that was filtered. Yield: 0.103 g (40%). 1H 491 
NMR (400 MHz, CDCl3): δ 8.44 [s, 3J(H–Pt) = 56.0; 1H, Hf ], 7.39–7.29 [m, 8H, Haromatic], 7.00 [d, 492 
3J(H–H) = 8.0; 1H, Hd], 6.87 [d, 3J(H–H) = 8.0; 2H, Hb], 6.81 [d, 4J(H–H) = 2.0; 3J(H–Pt) = 72.0; 1H, 493 
Hc], 5.16 [s, 2H, Hg], 2.28 [q, 3J(H–H) = 7.6; 4H, Hl], 2.27 [s, 3H, Hk], 1.04 [t, J(H–H) = 7.6; 6H, Hm]. 494 
Anal.: calc. C25H28ClNPtS·H2O (%): C, 48.19; H, 4.85; N, 2.25; S, 5.15. Found (%): C, 47.42; H, 495 
4.76; N, 2.48; S, 3.99. MS-ESI(+): m/z: 514.07 [M-tolyl + H]+, 531.10 [M-tolyl + H2O]+. 496 
[Pt(4-CH3C6H4){(C6H5CH2)NCH(4-ClC6H3)}P(C6H5)3] (cm3). This compound was obtained 497 
mixing 0.050 g (0.08 mmol) of compound cm2 with 0.021 g (0.08 mmol) of PPh3 in 10 mL of acetone. 498 
The mixture was stirred at room temperature for 2 h and evaporated to dryness, obtaining a yellow oil. 499 
The residue was treated with diethyl ether and filtered to afford a crystalline yellow solid. Yield: 0.022 g 500 
(34%). 1H NMR (400 MHz, CDCl3): δ 8.10 [s, 3J(H–Pt) = 52.0; 1H, Hf ], 7.53–7.49 [m, 6H, 501 
Haromatic], 7.35–7.32 [m, 3H, Haromatic], 7.25–7.22 [m, 10H, Haromatic], {7.18 [dd, 3J(H–H) = 8.0; 502 
4J(H–H) = 2.0; 1H]; 6.96 [dd, 3J(H–H) = 8.0; 4J(H–H) = 2.0; 1H] Hd,e}, 6.91 [d, 3J(H–H) = 8.0; 2H, 503 
Ha], 6.80–6.78 [m, 2H, Haromatic], 6.44 [d, 3J(H–H) = 8.0; 2H, Hb], 4.09 [s, 2H, Hg], 2.10 [s, 3H, Hk]. 504 
31P{1H} NMR (161.98, CDCl3): δ 26.90 [1J (P–Pt) = 2201.31]. Anal.: calc. C39H33ClNPPt·H2O (%): 505 
C, 58.90; H, 4.43; N, 1.76. Found (%): C, 58.74; H, 4.73; N, 1.78. MS-ESI(+): m/z: 778.18 [M + H]+, 506 
795.20 [M + H2O]+, 819.20 [M + CH3CN + H]+. 507 
 508 
Cyclometallated platinum(IV) compounds: synthesis and characterization 509 
[PtI2(4-CH3C6H4){(CH3)2N(CH2)3NCH(4-ClC6H3)}] (cm1I2). This compound was obtained from 510 
0.051 g (0.10 mmol) of compound cm1 and 0.025 g (0.10 mmol) of I2 in 10 mL of acetone. The mixture 511 
was stirred at room temperature for 2 h and filtered giving an intense orange solid. Yield: 0.054 g (71%). 512 
1H NMR (400 MHz, CDCl3): δ 8.43 [d, 3J(H–H) = 8.4; 3J(H–Pt) = 37.2; 2H, Ha], 8.13 [s, 3J(H–Pt) = 513 
42.4; 1H, Hf ], 7.37 [d, 3J(H–H) = 8.4; 1H, He], 7.04 [d, 4J(H–H) = 1.6; 3J(H–Pt) = 36.8; 1H, Hc], 6.88 514 
[dd, 3J(H–H) = 7.2; 4J(H–H) = 1.6; 1H, Hd], 6.85 [d, 3J(H–H) = 8.0; 2H, Hb], 4.14 [m, 2H, Hg], 3.14 515 
[m, 2H, Hh], 3.04 [s, 3J(H–Pt) = 16.8; 6H, Hj], 2.35 [s, 3H, Hk], 2.27 [m, 2H, Hi]. 195Pt NMR (85.68 516 
MHz, CDCl3): δ −3068.9 (s). Anal.: calc. C19H23ClI2N2Pt (%): C, 29.88; H, 3.04; N, 3.67. Found (%): 517 
C, 29.18; H, 2.87; N, 3.53. MS-ESI(+): m/z: 637.03 [M − I]+, 781.97 [M + NH4]+, 763.94 [M + H]+. 518 
[PtCH3I(4-CH3C6H4){(CH3)2N(CH2)3NCH(4-ClC6H3)}] (cm1MeI). A 0.050 g (0.10 mmol) portion 519 
of cm1 and 1 mL of CH3I were combined in 10 mL of acetone, and the mixture was stirred at room 520 
temperature for 24 h. The solvent was eliminated and the residue was treated with diethyl ether and 521 
filtered to afford a yellow solid. Yield: 0.045 g (70%). 1H NMR (400 MHz, CDCl3): δ 8.64 [d, 3J(H–H) 522 
= 8.0; 3J(H–Pt) = 42.4; 1H, Ha], 8.42 [s, 3J(H–Pt) = 48.0; 1H, Hf ], 7.32 [d, 3J(H–H) = 8.0; 4J(H–Pt) =  523 
8.0; 1H, He], 7.12 [d, 3J(H–H) = 8.0; 3J(H–Pt) = 38.0; 1H, Ha′], 6.99 [dd, 3J(H–H) = 8.0; 4J(H–H) = 524 
2.0; 1H, Hd], 6.92 [d, 3J(H–H) = 8.0; 2H, Hb], 6.90 [d, 4J(H–H) = 2.0; 3J(H–Pt) = 48.4; 1H; Hc], {4.43 525 
[t, 3J(H–H) = 14.0; 1H]; 4.00 [dt, 2J(H–H) = 12.0; 3J(H–H) = 4.0; 1H]; 3.82 [t, 3J(H–H) = 12.0; 1H]; 526 
2.65 [dd, 2J(H–H) = 13.6; 3J(H–H) = 7.2; 1H]; 2.06 [m, 2H] Hg,h,i}, 2.80 [s, 3J(H–Pt) = 13.6; 3H, Hj], 527 
2.47 [s, 3J(H–Pt) = 16.8; 3H, Hj′], 2.33 [s, 3H, Hk], 1.31 [s, 2J(H–Pt) = 68.0; 3H, Me-Pt]. 195Pt NMR 528 
(85.68 MHz, CDCl3): δ −2310.9 (s). Anal.: calc. C20H26ClIN2Pt (%): C, 36.85; H, 4.02; N, 4.30. 529 
Found (%): C, 36.54; H, 4.02; N, 4.07. MS-ESI(+): m/z: 433.08 [M− I-tolyl]+, 509.11 [M− Me − I]+, 530 
651.04 (calc. 651.05) [M]+. 531 
PtI2(4-CH3C6H4){(C6H5CH2)NCH(4-lC6H3)}(S(CH2CH3)2)] (cm2I2). The compound was obtained 532 
from 0.051 g (0.08 mmol) of cm2 and 0.026 g (0.10 mmol) of I2 in 10 mL of acetone. The mixture was 533 
stirred at room temperature for 2 h and filtered, obtaining an intense orange solid. Yield: 0.052 g (72%). 534 
MS-ESI(+): m/z: 786.92 [M − SEt2 + H2O + H]+, 658.00 [M − SEt2 − I + H2O]+, 875.97 [M + NH4]+, 535 
514.08 [M − SEt2 − 2I]+, 1555.80 [2M − 2SEt2 + NH4]+. 536 
[PtCH3I(4-CH3C6H4){(C6H5CH2)NCH(4-ClC6H3)}(S(CH2CH3)2) (cm2MeI). A 0.052 g (0.09 537 
mmol) portion of cm2 and 1 mL of CH3I were combined in 10 mL of acetone, and the mixture was 538 
stirred at room temperature for 24 h. The solvent was removed and the residue obtained was treated with 539 
hexane and filtered to afford a yellow solid. Yield: 0.046 g (72%).1H NMR (400 MHz, CDCl3): δ 7.85 540 
[s,3J(H–Pt) = 45.6; 1H, Hf ], 7.47–7.36 [m, 6H, Haromatic], 7.13–7.08 [m, 2H, Haromatic], 7.04–7.01 541 
[m, 1H], 6.94 [dd, 3J(H–H) = 8.0, 1.8, 1H, Haromatic], 6.91 [d, 3J(H–H) = 7.0, 2H], 5.78 [d, 3J(H–H) = 542 
1.6; 1H, Hg], 5.76 [d, 3J(H–H) = 1,6; 1H, Hg′], 3.50 [m, 4H, Hl], 2.30 [s, 3H, Hk], 1.77 [s, 3J(H–Pt) = 543 
72.0, Me-Pt], 1.45 [t, 3J(H–H) = 7.6; 6H, Hm]. Anal.: calc. C26H31ClINPtS (%): C, 41.80; H, 4.18; N, 544 
1.88; S, 4.29. Found (%): C, 41.56; H, 4.18; N, 1.77; S, 4.07. MS-ESI(+): m/z: 528.09 [M-tolyl − I]+, 545 
604.12 [M − Me − I]+.  546 
[PtI2(4-CH3C6H4){(C6H5CH2)NCH(4-ClC6H3)}P(C6H5)3] (cm3I2). This compound was obtained 547 
from 0.040 g (0.05 mmol) of cm3 and 0.017 g (0.07 mmol) of I2 in 10 mL of acetone. The mixture was 548 
stirred for 2 h at room temperature, and the solvent was evaporated to dryness to obtain a brown oil. The 549 
residue was treated with diethyl ether and filtered, giving an orange solid. Yield: 0.030 g (57%). MS-550 
ESI(+): m/z: 1049.00 [M + NH4]+, 904.07 [M − I]+, 776.16 [M − 2I]+. 551 
[PtCH3I(4-CH3C6H4){(C6H5CH2)NCH(4-ClC6H3)}P(C6H5)3] (cm3MeI). A 0.071 g (0.09 mmol) 552 
amount of cm3 and 1 mL of CH3I were combined in 10 mL of acetone. The mixture was stirred at room 553 
temperature for 24 h. The solution was filtered to obtain a white solid. Yield: 0.028 g (33%). 1H NMR 554 
(400 MHz, CDCl3): δ 7.76 [d, 4J(H–H) = 1.2; 3J(H–Pt) = 49.2; 1H, Hf ], 7.47–7.38 [m, 8H, Haromatic], 555 
7.32–7.28 [m, 9H, Haromatic], 7.12–6.95 [m, 5H, Haromatic], 6.80 [dd, 3J(H–H) = 8.0; 4J(H–H) = 2.8; 556 
Haromatic], 6.70 [dd, J(H–H) = 8.0; J(H–H) = 2.8, 2H, Haromatic], 6.45 [s, 3J(H–Pt) = 46.4; 1H, Hc], 557 
{5.39 [dd, 4J(H–H) = 18.0; 4J(H–H) = 2.4; 1H], 4.57 [dd, 4J(H–H) = 18.0; 4J(H–H) = 1.6; 1H], Hg}, 558 
2.18 [s, 3H, Hk], 1.85 [d, 3J(H–P) = 8.0; 2J(H–Pt) = 72.0; 3H, Me-Pt]. 31P{1H} (161.98 MHz, CDCl3): 559 
δ −9.47 [1J (P–Pt) = 989.7]. Anal.: calc. C40H36ClINPPt (%): C, 52.27; H, 3.95; N, 1.52. Found (%): 560 
C, 51.94; H, 4.22; N, 1.61. MS-ESI(+): m/z: 792.20 [M − I]+. 561 
 562 
Stability and behaviour in presence of ascorbic acid, glutathione (GSH) and L-cysteine by NMR 563 
measurements 564 
The stability of the platinum(IV) compounds under investigation in aqueous solution was monitored by 565 
1H NMR spectroscopy at ambient temperature. Samples were analysed in the Nuclear Magnetic 566 
Resonance Unit, Scientific and Technological Centres of the University of Barcelona (CCiTUB). 567 
Solutions of the complexes were prepared in 50 mM phosphate buffer (in D2O, pD 7,40) and minimum 568 
amount (2 drops) of d6-DMSO for solubilisation of the compound. Final concentration of the complex 569 
was 1 mM and 1H NMR spectra were recorded with a Varian 400 and a Bruker 400 spectrometer at time 570 
periods between 0 h–1 week. For monitoring the reactivity of the studied compounds with ascorbic acid, 571 
GSH or L-cysteine, the samples were prepared in the same conditions described above with a final 572 
concentration of complex and ascorbic acid, GSH or L-cysteine of 1 mM and 25 mM, respectively. 1H 573 
NMR spectra were recorded over the same time period as above. 574 
 575 
Crystal data and structure refinement for cm3 576 
A yellow prism-like specimen of cm3, grown in dichloromethane–methanol at room temperature, was 577 
used for the X-ray crystallographic analysis. X-ray intensity data were collected on a D8 Venture system 578 
equipped with a multilayer monochromator and a Mo microfocus (λ = 0.71073 Å) at 100 K. The 579 
structure was solved and refined at the Unitat de Difracció de RX (CCiTUB) using the Bruker SHELXT 580 
software package.57 Further information is given in Table 4. 581 
 582 
Biological studies 583 
Cell culture and cell viability assay. Human lung adenocarcinoma A-549 cells and human breast 584 
adenocarcinoma MDA-MB-231 cells were grown as a monolayer culture in minimum essential medium 585 
(DMEM (Dulbecco’s Modified Eagle Medium) with L-glutamine, without glucose and without sodium 586 
pyruvate) with addition of 10% heat-inactivated Fetal Calf Serum (FCS), 10 mM D-glucose and 0.1% 587 
streptomycin/ penicillin, in standard culture conditions (humidified air with 5% CO2 at 37 °C). Human 588 
breast adenocarcinoma MCF-7 cells were cultured in MEM without phenol red, containing 10% Fetal 589 
Bovine Serum (FBS), 10 mM D-glucose, 1 mM sodium pyruvate, 2 mM L-glutamine, 0.1% 590 
streptomycin/penicillin, 0.01 mg ml−1 insulin, and 1% non-essential amino acids. Human colorectal 591 
carcinoma HCT116 cells were cultured in DMEM/HAM F12 (1 : 1 volume) mixture containing 10% 592 
FBS, 4 mML-glutamine, 12.5 mM D-glucose and 0.1% streptomycin/ penicillin. 593 
For all viability assays, compounds were suspended in high purity DMSO at 20 mM as stock solution. 594 
To obtain final assay concentrations, they were diluted in DMEM (final concentration of DMSO was the 595 
same for all conditions, and was always lower than 1%). The assay was performed by a variation of the 596 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay described by Mosmann et 597 
al.58 and Matito and coworkers59 which is based on the ability of live cells to cleave the tetrazolium 598 
ring of the MTT thus producing formazan, which absorbs at 550 nm. In brief, the corresponding number 599 
of cells per well (2.5 × 103 A-549 cells per well, 5 × 103 MDA-MB-231 cells per well, 1 × 104 MCF-7 600 
cells per well and 2 × 103 HCT-116 cells per well) were cultured in 96 well plates for 24 hours prior to 601 
the addition of different compounds at different concentrations, in triplicate. After incubation of the cells 602 
with the compounds for 72 h more, the media was aspirated and 100 μL of filtered MTT (0.5 mg mL−1) 603 
were added to each well. Following 1 h of incubation with the MTT, the supernatant was removed and 604 
the precipitated formazan was dissolved in 100 μL DMSO. Relative cell viability, compared to the 605 
viability of untreated cells, was measured by absorbance at 550 nm on an ELISA plate reader (Tecan 606 
Sunrise MR20-301, TECAN, Salzburg, Austria). Concentrations that inhibited cell growth by 50% 607 
(IC50) after 72 h of treatment were subsequently calculated. 608 
DNA migration studies. A stock solution (10 mM) of compounds cm1, cm2, cm3, cm1MeI, cm1I2, 609 
cm2MeI and cm3MeI was prepared in high purity DMSO. Then, serial dilutions were made in MilliQ 610 
water (1 : 1). Plasmid pBluescript SK + (Stratagene) was obtained using a QIAGEN plasmid midi kit as 611 
described by the manufacturer. Interaction of drugs with pBluescript SK + plasmid DNA was analysed 612 
by agarose gel electrophoresis. Plasmid DNA aliquots (40 μg mL−1) were incubated in TE buffer (10 613 
mM Tris-HCl, 1 mM EDTA, pH 7.5) with different concentrations of compounds mentioned above 614 
ranging from 0 μM to 200 μM at 37 °C for 24 h. Cisplatin and ethidium bromide (EB) were used as a 615 
reference controls. Aliquots of 20 μL of the incubated solutions containing 0.3 μg of DNA were 616 
subjected to 1% agarose gel electrophoresis in TAE buffer (40 mM tris-acetate, 2 mM EDTA, pH 8.0). 617 
The gel was stained in TAE buffer containing ethidium bromide (0.5 mg mL−1) and visualized and 618 
photographed under UV light. 619 
Topoisomerase I-based experiments were performed as described previously.60 Supercoiled pBluescript 620 
DNA, obtained as described above, was treated with topoisomerase I in the absence or presence of 621 
compounds mentioned previously. Assay mixtures contained supercoiled pBluescript DNA (0.3 μg), calf 622 
thymus topoisomerase I (3 units) and complexes cm1, cm2, cm3, cm1I2, cm1MeI, cm2MeI and cm3MeI 623 
(100 μM) in 20 μL of relaxation buffer Tris-HCl buffer (pH 7.5) containing 175 mM KCl, 5 mM MgCl2 624 
and 0.1 mM EDTA. Reactions were incubated for 30 min at 37 °C and stopped by the addition of 2 μL 625 
of agarose gel loading buffer. Samples were then subjected to electrophoresis and DNA bands stained 626 
with ethidium bromide as described above. 627 
Topoisomerase IIα activity was determined by incubating 0.3 μg of supercoiled pBluescript DNA with 628 
topoisomerase Iiα (3 units) in the absence or presence of increasing concentrations (5–100 μM) of 629 
compounds cm1I2, cm2MeI, cm1MeI and cm3MeI, and 200 μM of compounds cm1, cm2 and cm3 in 20 630 
μL of topoisomerase II buffer for 40 min at 37 °C. The reaction was stopped by the addition of 2 μL of 631 
agarose gel loading buffer. Samples were then subjected to electrophoresis and DNA brands stained 632 
with ethidium bromide as described above. 633 
Cathepsin B inhibition assay. The fluorimetric cathepsin B assay was performed following 634 
manufacturer’s instructions (Sigma-Aldrich). Briefly, the reaction mixture contained 48 mM sodium 635 
phosphate (pH 6.0), 4.0 mM EDTA, 352 mM potassium phosphate buffer, 2.5 mM L-cysteine HCl 636 
solution 0.03% Brij 35 solution and 0.02 mM Nα-carbobenzoxy-Arg-Arg-7- amido-4-methylcoumarin 637 
as substrate. To test the inhibitory effect of the platinum compounds on cathepsin B, activity 638 
measurements were performed in duplicate using fixed concentrations of enzyme (0.5 units) and 639 
substrate (20 μM). The platinum compounds were used at two concentrations (50 μM and 100 μM). 640 
Before the addition of substrate, cathepsin B was incubated with the different compounds at 37 °C for 1 641 
h. The cysteine proteinase inhibitor E-64 was used as a positive control of cathepsin B inhibition. 642 
Complete inhibition was achieved at 10 μM concentration of E-64. Activity was measured over 5 min 643 
on a fluorescence spectrophotometer (excitation = 348 nm, emission = 440 nm). 644 
Cell cycle analysis. Cell cycle was assessed by flow cytometry using a fluorescence activated cell sorter 645 
(FACS). For this assay, 2.5 × 104 HCT-116 cells were seeded in 6 well plates with 2 mL of growth 646 
medium. After 24 h of incubation, compounds cm1MeI or cm1I2 were added at their IC50 values 1.78 647 
and 5.14 μM, respectively. Following 72 h of incubation, cells were harvested by mild tripsinization, 648 
collected by centrifugation and fixed in 70% ethanol and stored at −20 °C until measure. Right before 649 
measuring, fixed cells were incubated with phosphate buffer solution (PBS) containing 50 mg mL−1 PI 650 
and 10 mg mL−1 DNase-free RNase. The cell suspension was incubated for 1 h at room temperature to 651 
allow for the staining of the cells with the PI, and afterwards FACS analysis was carried out at 488 nm 652 
by employing a CyAn flow cytometer (Beckman Coulter). Data from 1 × 104 cells were collected and 653 
analysed using the FlowJo software. 654 
 655 
Apoptosis assay 656 
Apoptosis was assessed evaluating the annexin-V binding to phosphatidylserine (PS), which is 657 
externalized early in the apoptotic process. 2.5 × 104 HCT-116 cells per well were seeded in 6 well 658 
plates with 2 mL of medium and treated as described for the cell cycle analysis assay. After cell 659 
collection and centrifugation, cells were resuspended in 95 μL binding buffer (10 mM HEPES/NaOH, 660 
pH 7.40, 140 mM NaCl, 2.5 mM CaCl2). 3 μL of Annexin-V FITC conjugate (1 mg mL−1) were then 661 
added and the suspension was incubated in darkness for 30 min, at room temperature. The cell 662 
suspension was added to a vial containing 500 μL of binding buffer, stained with 20 μL of 1 mg mL−1 663 
PI solution and analysed. Data from 1 × 104 cells were collected and analysed using the FlowJo 664 
software. 665 
Determination of intracellular reactive oxygen species (ROS) levels. 2.5 × 104 HCT-116 cells per well 666 
were seeded in 6 well plates with 2 mL of growth medium and treated as described for the cell cycle 667 
analysis assay. Cells were collected and intracellular ROS was measured at 24, 48 and 72 h. First, cells 668 
were washed once with warm PBS, and incubated with 5 μM 2′,7′- dichlorofluorescein diacetate 669 
(DCFH-DA, Invitrogen) in PBS supplemented with 10 mM glucose and 2 mM glutamine for 30 min at 670 
37 °C. Then, DCFH-DA solution in PBS was replaced with complete culture medium and the cells were 671 
incubated for another 30 min at 37 °C. Finally, cells were trypsinised and resuspended thoroughly in 0.4 672 
mL of PBS containing DCFH-DA (50 μM) and PI (20 μg mL−1).61 Intracellular internalized probe 673 
reacts with ROS and emits fluorescence when excited at 492 nm. Emitted fluorescence was recorded by 674 
flow cytometry at 520 nm using a CyAn flow cytometer (Beckman Coulter). Data of DCF fluorescence 675 
concentrations from 1 × 104 PI negative cells were collected and analysed using FlowJo software. 676 
 677 
 678 
 679 
Data analysis 680 
For each compound, a minimum of three independent experiments with triplicate values were conducted 681 
to measure cell viability. A minimum of two independent experiments in triplicates were performed for 682 
cell cycle analysis, assessment of apoptosis and ROS. Significant differences compared to control were 683 
assessed by Student’s t-test where p < 0.05(*), p < 0.01(**) or p < 0.001(***) were taken into 684 
consideration. Data are given as the mean ± standard deviation (SD). 685 
 686 
 687 
 688 
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Legends to figures 805 
 806 
Scheme 1 Previously studied cyclometallated platinum(IV) compounds 807 
 808 
Scheme 2 New cyclometallated platinum(II) compounds used as precursors in this work. 809 
 810 
Scheme 3 Synthesis of the cyclometallated platinum(II) and platinum(IV) compounds. (i) Toluene, 90 811 
°C, 6 h; (ii) toluene, RT, 24 h; (iii) +PPh3, acetone, 2 h; (iv) +CH3I, acetone, RT, 24 h; (v) +I2, acetone, 812 
RT, 2 h (the numbering scheme used in the Experimental section and in Table 1 is shown). 813 
 814 
Scheme 1. Synthesis of Platinum(II) Compoundsa 815 
 816 
Figure. 1. Molecular structure of compound cm3 (molecule a). Selected bond lengths (Å) and angles (°) 817 
with estimated standard deviations: Pt1a–C1a, 1.998(5); Pt1a–C8a, 2.068(4); Pt1a–N1a, 2.154(4); Pt1a–818 
P1a, 2.2996(11); N1a–C14a, 1.295(5); N1a–C15a, 1.475(6); C8a–C13a, 1.434(7); C13a–C14a, 1.427(6); 819 
C1a–Pt1a–C8a, 89.33(19); C8a–Pt1a–N1a, 79.91(17); C1a–Pt1a–P1a, 89.38(12); N1a–Pt1a–P1a, 820 
101.50(10). Hydrogens are omitted for clarity. 821 
 822 
Scheme 4 Oxidative addition of methyl iodide followed by isomerisation. 823 
 824 
Scheme 5 Proposed species formed in solution (the charges of the ionic species are omitted). 825 
 826 
Figure. 2. Antiproliferative activity of cyclometallated platinum(II) cm1 and cm2 and cyclometallated 827 
platinum(IV) compounds cm1I2, cm1MeI and cm2MeI, and cisplatin (IC50 μM) against A-549 lung, 828 
MDA-MB-231 and MCF-7 breast, and HCT-116 colon human cancer cell lines. Compounds cm3 and 829 
cm3MeI with high IC50 values or even IC50 values >100 in several cancer cell lines are not shown. 830 
 831 
Figure. 3. Antiproliferative activity of cyclometallated platinum(IV) compound cm1I2 (IC50 μM) 832 
against BJ fibroblast human normal cells line and A-549 lung, MDA-MB-231 and MCF-7 breast, and 833 
HCT-116 colon human cancer cells lines. 834 
 835 
Figure. 4 Antiproliferative activity of cyclometallated platinum(IV) compound cm1MeI (IC50 μM) 836 
against BJ normal cells and A-549 lung, MDA-MB-231 and MCF-7 breast, and HCT-116 colon human 837 
cancer cell lines. 838 
 839 
Figure. 5. Interaction of pBluescript SK+ plasmid DNA (0.3 μg) with ethidium bromide (EB), cisplatin 840 
and increasing concentrations of compounds under study. Lane 1: DNA only. Lane 2: 0.5 μM. Lane 3: 1 841 
μM. Lane 4: 2.5 μM. Lane 5: 5 μM. Lane 6: 10 μM. Lane 7: 25 μM. Lane 8: 50 μM. Lane 9: 100 μM. 842 
Lane 10: 200 μM; sc = supercoiled closed circular DNA; oc = open circular DNA.. 843 
 844 
Figure. 6. Analysis of compounds under study as putative DNA intercalators or topoisomerase I 845 
inhibitors. Conversion of supercoiled pBluescript plasmid DNA (0.3 μg) incubated at 37 °C to relaxed 846 
DNA by 847 
the action of topoisomerase I (3 units) in the absence or in the presence 848 
of compounds in a 100 μM concentration was analysed by agarose gel. 849 
Lane P: scDNA only. Lane T: Topoisomerase I (3 units) + 0 μM drug. 850 
Lane 1: cm1. Lane 2: cm2. Lane 3: cm3. Lane 4: cm1I2. Lane 5: cm1MeI. 851 
Lane 6: cm2MeI. Lane 7: cm3MeI; sc = supercoiled closed circular DNA; 852 
oc = open circular DNA.. 853 
 854 
Figure 7. Analysis of compounds under study as topoisomerase IIα inhibi-tors. Conversion of 855 
supercoiled pBluescript plasmid DNA (0.3 μg) incubated at 37 °C to relaxed DNA by the action of 856 
topoisomerase Iiα (3 units) in the absence or in the presence of increasing amount of compounds  857 
was analysed by agarose gel. Lane E: topoisomerase IIα + 0 μM drug. Lane 1: scDNA only. Lane 2: 5 858 
μM. Lane 3: 10 μM. Lane 4: 25 μM. Lane 5: 50 μM. Lane 6: 100 μM. Lane 7: 200 μM; sc = supercoiled 859 
closed circular DNA; oc = open circular DNA 860 
 861 
Figure 8. Cell cycle phase distribution at 72 h incubation with compounds cm1MeI and cm1I2 at their 862 
IC50 concentration in HCT-116 colon cancer cell line. Cells were stained with propidium iodide (PI) 863 
and their DNA content was analysed by flow cytometry. 864 
 865 
Figure 9. Percentage variations of alive, early apoptotic and late apoptotic/ necrotic cell populations at 866 
72 h incubation with compounds cm1MeI and cm1I2 at their IC50 concentration in HCT-116 colon 867 
cancer cell line. Cells were stained with propidium iodide (PI) and FITC-annexin and were analysed by 868 
flow cytometry. 869 
 870 
Figure 10 ROS levels after 24, 48 and 72 h incubation with compounds cm1MeI and cm1I2 at their 871 
IC50 concentration in HCT-116 colon cancer cell line. 872 
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